Clinical Trial: Evaluation of the Safety and Efficacy of GB-0998 in Unexplained Primary Recurrent Miscarriage

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: A Randomized, Placebo-controlled, Double-blinded Study With GB-0998 for Unexplained Primary Recurrent Miscarriage

Brief Summary: To estimate the safety and efficacy of intravenous immunoglobulin therapy using GB-0998 in women with four or more miscarriages by carrying out randomized, placebo-controlled, double-blinded study．

Detailed Summary:
Sponsor: Japan Blood Products Organization

Current Primary Outcome: Rate of continued pregnancy [ Time Frame: at the beginning of 22th gestational week ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Japan Blood Products Organization

Dates:
Date Received: July 3, 2014
Date Started: April 2014
Date Completion: June 2019
Last Updated: March 6, 2017
Last Verified: March 2017